Iilun Murphy, M.D., serves as the Director of the Office of Generic Drugs (OGD) in the Center for Drug Evaluation and Research (CDER). This office is responsible for the review and approval of abbreviated new drug applications. OGD’s mission is to ensure, through a scientific and regulatory process, that generic drugs are safe and effective for the American public.
Dr. Murphy began her FDA career in 2007 as a medical officer in CDER’s Office of New Drugs, Division of Gastroenterology Products. In 2011 she joined the Center for Tobacco Programs, where she expanded the newly established Office of Science. Dr. Murphy rejoined CDER in January 2020 as OGD’s Deputy Director for Clinical and Regulatory Affairs. She oversaw the implementation of the Generic Drug User Fee Amendments’ goals and review management activities. She was instrumental in leading OGD’s 2021-2022 reorganization and served as acting director for OGD’s new Office of Safety and Clinical Evaluation. Dr. Murphy was integral in the creation of the first Generic Drug Global Cluster, a collaborative forum for the world’s leading regulatory agencies.
Dr. Murphy is a board-certified pediatrician and an assistant clinical professor of pediatrics at The George Washington University School of Medicine. She earned her bachelor’s degree from Cornell University and her medical degree from Stanford University.